Weekly roundup: Poolbeg’s progress, Asabys’ strategic expansion, and what to expect at Optimum’s Healthcare Investor Conference

/in

Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025 Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announced its unaudited interim results for the six months to 30 June 2025. The company says its well-funded with multiple upcoming clinical milestones. Asabys Partners integrates Aliath Bioventures […]

Read more

Hot topic: Conference season is upon us – are you ready?

/in

Back in late June, we wrote in Hot Topic about the importance of preparing early for conference season. Well, the last three months have flown by! Memories of the long hot summer are fading, and we are now all truly ‘back at school’. And as we all know from our school days, the busy autumn […]

Read more

Weekly roundup: Breakthrough trials, strategic partnerships, and investor insights

/in

This week’s roundup captures the accelerating pace of innovation across the global biotech and pharmaceutical landscape. From Hansa Biopharma’s landmark Phase 3 trial success in kidney transplantation to DaltonTx’s £4 million seed raise for AI-driven drug discovery, the sector is brimming with breakthroughs. Xeltis, Poolbeg Pharma, and Heidelberg Pharma are all advancing important trials, while […]

Read more

Hot topic: Getting more bang for each biotech buck

/in

Biotech investors like to think that their actions benefit society, by bringing to the market new drugs that save lives and spare people illness. And often they do. In many cases, only by them risking their capital, is great good done. Think of the early investors in BioNTech or Moderna, for instance. Without them, mRNA […]

Read more

Weekly roundup: Clearance, Capital & Copenhagen: A week in review!

/in

AMS announced its Interim results for the six months ended 30 June 2025 This week Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announced its unaudited interim results for the six months ended 30 June 2025. Group revenue increased by 63% to £110.8 million and by 66% at constant currency […]

Read more